Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesuparib in Platinum-resistant Ovarian Cancer
NCT05475184Phase 2Active, not recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nesuparib in ovarian cancer, sponsored by Onconic Therapeutics Inc.. Started Aug 2022; status: active, not recruiting.
02
Drugs
nesuparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05475184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475184.